{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:53:48Z","timestamp":1793148828068,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T00:00:00Z","timestamp":1593129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T00:00:00Z","timestamp":1593129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["not applicable"],"award-info":[{"award-number":["not applicable"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2020,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>With the recent approval of the combinations of axitinib with the immune checkpoint inhibitor (ICI) pembrolizumab or avelumab for first-line treatment of advanced renal cell carcinoma, guidance on how to distinguish between immune-related adverse events (AEs) caused by ICI versus axitinib-related AEs is necessary to optimise therapy with axitinib\u2013ICI combinations. The recommendations here are based on (1) systematic review of published evidence, (2) discussion among experts in the field and (3) a survey to obtain expert consensus on specific measures for therapy management with the combinations axitinib\/avelumab and axitinib\/pembrolizumab. The experts identified areas of AEs requiring unique management during treatment with axitinib\u2013ICI combinations that were not covered by current recommendations. Diarrhoea, hepatic toxicity, fatigue and cardiovascular AEs were found to be applicable to such specialised management. Triage between immune-suppressive and supportive measures is a key component in therapy management. Clinical monitoring and experience with both classes of agents are necessary to manage this novel therapeutic approach. We focused on AEs with an overlap between axitinib and ICI therapy. Our recommendations address AE management of axitinib\u2013ICI combinations with the aim to improve the safety of these therapies.<\/jats:p>","DOI":"10.1038\/s41416-020-0949-9","type":"journal-article","created":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T23:07:44Z","timestamp":1593126464000},"page":"898-904","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events"],"prefix":"10.1038","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2083-7687","authenticated-orcid":false,"given":"Viktor","family":"Gr\u00fcnwald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin H.","family":"Voss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian I.","family":"Rini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Powles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Albiges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel H.","family":"Giles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Jonasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,26]]},"reference":[{"key":"949_CR1","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","volume":"370","author":"B Escudier","year":"2007","unstructured":"Escudier, B., Pluzanska, A., Koralewski, P., Ravaud, A., Bracarda, S., Szczylik, C. et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370, 2103\u20132111 (2007).","journal-title":"Lancet"},{"key":"949_CR2","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/S1470-2045(13)70465-0","volume":"14","author":"TE Hutson","year":"2013","unstructured":"Hutson, T. E., Lesovoy, V., Al-Shukri, S., Stus, V. P., Lipatov, O. N., Bair, A. H. et al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol. 14, 1287\u20131294 (2013).","journal-title":"Lancet Oncol."},{"key":"949_CR3","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","volume":"27","author":"RJ Motzer","year":"2009","unstructured":"Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Oudard, S. et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 3584\u20133590 (2009).","journal-title":"J. Clin. Oncol."},{"key":"949_CR4","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115\u2013124 (2007).","journal-title":"N. Engl. J. Med."},{"key":"949_CR5","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","volume":"28","author":"CN Sternberg","year":"2010","unstructured":"Sternberg, C. N., Davis, I. D., Mardiak, J., Szczylik, C., Lee, E., Wagstaff, J. et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J. Clin. Oncol. 28, 1061\u20131068 (2010).","journal-title":"J. Clin. Oncol."},{"key":"949_CR6","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.ejca.2012.12.010","volume":"49","author":"CN Sternberg","year":"2013","unstructured":"Sternberg, C. N., Hawkins, R. E., Wagstaff, J., Salman, P., Mardiak, J., Barrios, C. H. et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and\/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur. J. Cancer 49, 1287\u20131296 (2013).","journal-title":"Eur. J. Cancer"},{"key":"949_CR7","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1200\/JCO.2019.37.7_suppl.546","volume":"37","author":"DG McDermott","year":"2019","unstructured":"McDermott, D. G., Lee, J. L., Ziobro, M., Gafanov, R. A., Matveev, V. B., Su\u00e1rez, C. et al. First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (NCC-RCC): results from KEYNOTE-427 cohort B. J. Clin. Oncol. 37, 546 (2019).","journal-title":"J. Clin. Oncol."},{"key":"949_CR8","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1803\u20131813 (2015).","journal-title":"N. Engl. J. Med."},{"key":"949_CR9","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1186\/s40425-019-0746-2","volume":"7","author":"UN Vaishampayan","year":"2019","unstructured":"Vaishampayan, U. N., Sch\u00f6ffski, P., Ravaud, A., Borel, C., Peguero, J., Chaves, J. et al. Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial. J. Immunother. Cancer 7, 275 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"949_CR10","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1096\/fj.05-4493com","volume":"20","author":"AE Dirkx","year":"2006","unstructured":"Dirkx, A. E., oude Egbrink, M. G., Castermans, K., van der Schaft, D. W., Thijssen, V. L., Dings, R. P. et al. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J. 20, 621\u2013630 (2006).","journal-title":"FASEB J."},{"key":"949_CR11","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/bs.ircmb.2016.09.007","volume":"330","author":"A Lapeyre-Prost","year":"2017","unstructured":"Lapeyre-Prost, A., Terme, M., Pernot, S., Pointet, A. L., Voron, T., Tartour, E. et al. Immunomodulatory activity of VEGF in cancer. Int Rev. Cell Mol. Biol. 330, 295\u2013342 (2017).","journal-title":"Int Rev. Cell Mol. Biol."},{"key":"949_CR12","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1111\/febs.13656","volume":"283","author":"C Liu","year":"2016","unstructured":"Liu, C., Workman, C. J. & Vignali, D. A. Targeting regulatory T cells in tumors. FEBS J. 283, 2731\u20132748 (2016).","journal-title":"FEBS J."},{"key":"949_CR13","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","volume":"380","author":"RJ Motzer","year":"2019","unstructured":"Motzer, R. J., Penkov, K., Haanen, J., Rini, B., Albiges, L., Campbell, M. T. et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1103\u20131115 (2019).","journal-title":"N. Engl. J. Med."},{"key":"949_CR14","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D. et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1116\u20131127 (2019).","journal-title":"N. Engl. J. Med."},{"key":"949_CR15","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.euo.2019.06.022","volume":"2","author":"G de Velasco","year":"2019","unstructured":"de Velasco, G., Bex, A., Albiges, L., Powles, T., Rini, B. I., Motzer, R. J. et al. Sequencing and combination of systemic therapy in metastatic renal cell carcinoma. Eur. Urol. Oncol. 2, 505\u2013514 (2019).","journal-title":"Eur. Urol. Oncol."},{"key":"949_CR16","unstructured":"ESMO Guidelines Committee. eUpdate\u2014Renal cell carcinoma treatment recommendations. https:\/\/www.esmo.org\/guidelines\/genitourinary-cancers\/renal-cell-carcinoma\/eupdate-renal-cell-carcinoma-treatment-recommendations-2. Accessed 9 March 2020 (2020)."},{"key":"949_CR17","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.euo.2019.09.002","volume":"2","author":"AW Hahn","year":"2019","unstructured":"Hahn, A. W., Klaassen, Z., Agarwal, N., Haaland, B., Esther, J., Ye, X. Y. et al. First-line treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis. Eur. Urol. Oncol. 2, 708\u2013715 (2019).","journal-title":"Eur. Urol. Oncol."},{"key":"949_CR18","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.3109\/0284186X.2013.782103","volume":"52","author":"S Kapadia","year":"2013","unstructured":"Kapadia, S., Hapani, S., Choueiri, T. K. & Wu, S. Risk of liver toxicity with the angiogenesis inhibitor pazopanib in cancer patients. Acta Oncol. 52, 1202\u20131212 (2013).","journal-title":"Acta Oncol."},{"key":"949_CR19","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.eururo.2019.05.022","volume":"76","author":"L Albiges","year":"2019","unstructured":"Albiges, L., Powles, T., Staehler, M., Bensalah, K., Giles, R. H., Hora, M. et al. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: immune checkpoint inhibition is the new backbone in first-line treatment of metastatic clear-cell renal cell carcinoma. Eur. Urol. 76, 151\u2013156 (2019).","journal-title":"Eur. Urol."},{"key":"949_CR20","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M. et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol. 36, 1714\u20131768 (2018).","journal-title":"J. Clin. Oncol."},{"key":"949_CR21","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","volume":"5","author":"I Puzanov","year":"2017","unstructured":"Puzanov, I., Diab, A., Abdallah, K., Bingham, C. O. 3rd, Brogdon, C., Dadu, R. et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J. Immunother. Cancer 5, 95 (2017).","journal-title":"J. Immunother. Cancer"},{"key":"949_CR22","doi-asserted-by":"publisher","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","volume":"6","author":"A Liberati","year":"2009","unstructured":"Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gotzsche, P. C., Ioannidis, J. P. et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 6, e1000100 (2009).","journal-title":"PLoS Med."},{"key":"949_CR23","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher, D., Liberati, A., Tetzlaff, J. & Altman, D. G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 6, e1000097 (2009).","journal-title":"PLoS Med."},{"key":"949_CR24","doi-asserted-by":"publisher","first-page":"iv264","DOI":"10.1093\/annonc\/mdy162","volume":"29","author":"J Haanen","year":"2018","unstructured":"Haanen, J., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J. et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 29, iv264\u2013iv266 (2018).","journal-title":"Ann. Oncol."},{"key":"949_CR25","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S1470-2045(18)30081-0","volume":"19","author":"MB Atkins","year":"2018","unstructured":"Atkins, M. B., Plimack, E. R., Puzanov, I., Fishman, M. N., McDermott, D. F., Cho, D. C. et al. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. Lancet Oncol. 19, 405\u2013415 (2018).","journal-title":"Lancet Oncol."},{"key":"949_CR26","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S1470-2045(18)30107-4","volume":"19","author":"TK Choueiri","year":"2018","unstructured":"Choueiri, T. K., Larkin, J., Oya, M., Thistlethwaite, F., Martignoni, M., Nathan, P. et al. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. Lancet Oncol. 19, 451\u2013460 (2018).","journal-title":"Lancet Oncol."},{"key":"949_CR27","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1007\/s00432-019-03002-1","volume":"145","author":"AR Abolhassani","year":"2019","unstructured":"Abolhassani, A. R., Schuler, G., Kirchberger, M. C. & Heinzerling, L. C-reactive protein as an early marker of immune-related adverse events. J. Cancer Res Clin. Oncol. 145, 2625\u20132631 (2019).","journal-title":"J. Cancer Res Clin. Oncol."},{"key":"949_CR28","first-page":"12319","volume":"8","author":"Y Wang","year":"2015","unstructured":"Wang, Y., Pei, F., Wang, X., Sun, Z., Hu, C. & Dou, H. Diagnostic accuracy of fecal lactoferrin for inflammatory bowel disease: a meta-analysis. Int J. Clin. Exp. Pathol. 8, 12319\u201312332 (2015).","journal-title":"Int J. Clin. Exp. Pathol."},{"key":"949_CR29","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s40262-013-0068-3","volume":"52","author":"Y Chen","year":"2013","unstructured":"Chen, Y., Tortorici, M. A., Garrett, M., Hee, B., Klamerus, K. J. & Pithavala, Y. K. Clinical pharmacology of axitinib. Clin. Pharmacokinet. 52, 713\u2013725 (2013).","journal-title":"Clin. Pharmacokinet."},{"key":"949_CR30","unstructured":"Merck & Co Inc. KEYTRUDA\u00ae (pembrolizumab) for injection, for intravenous use, prescribing information. https:\/\/www.merck.com\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf. Accessed 18 May 2020 (2014)."},{"key":"949_CR31","unstructured":"EMD Serono Inc. BAVENCIO\u00ae (avelumab) injection, for intravenous use, prescribing information. https:\/\/www.emdserono.com\/content\/dam\/web\/corporate\/non-images\/country-specifics\/us\/pi\/bavencio-pi.pdf. Accessed 10 September 2019 (2017)."},{"key":"949_CR32","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1007\/s00520-018-4318-7","volume":"26","author":"CM O\u2019Higgins","year":"2018","unstructured":"O\u2019Higgins, C. M., Brady, B., O\u2019Connor, B., Walsh, D. & Reilly, R. B. The pathophysiology of cancer-related fatigue: current controversies. Support Care Cancer 26, 3353\u20133364 (2018).","journal-title":"Support Care Cancer"},{"key":"949_CR33","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y. et al. Fulminant myocarditis with combination immune checkpoint blockade. N. Engl. J. Med. 375, 1749\u20131755 (2016).","journal-title":"N. Engl. J. Med."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-020-0949-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-020-0949-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-020-0949-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:09:02Z","timestamp":1684616942000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-0949-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,26]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,9,15]]}},"alternative-id":["949"],"URL":"https:\/\/doi.org\/10.1038\/s41416-020-0949-9","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,26]]},"assertion":[{"value":"18 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"V.G. received commercial research grants from AstraZeneca, Bristol-Myers Squibb, Novartis, Pfizer and MSD; travel\/accommodation costs from Bristol-Myers Squibb, Ipsen, Roche, Pfizer and AstraZeneca; was a consultant\/advisory board member for AstraZeneca, Bayer, Bristol-Myers Squibb, EUSA Pharma, Ipsen, Pfizer, MSD, Lilly, PharmaMar, Novartis, Nanobiotix, Merck KGaA\/EMD Serono, Janssen-Cilag, Exelixis, Roche, Eisai and Cerulean. M.H.V. received commercial research grants from Bristol-Myers Squibb, Pfizer and Genentech\/Roche; honoraria from Novartis; travel\/accommodation costs from Eisai, Novartis, Takeda and AstraZeneca; was a consultant\/advisory board member for Alexion Pharmaceuticals, Bayer, Calithera Biosciences, Corvus Pharmaceuticals, Exelixis, Eisai, GlaxoSmithKline, Natera, Novartis and Pfizer. E.J. received commercial research grants from Exelixis, Novartis and Pfizer; was a consultant\/advisory board member for Eisai, Exelixis, Genentech, Ipsen, Novartis and Pfizer. T.P. received research funding from AstraZeneca, Roche, MSD, Bristol-Myers Squibb; was a consultant\/advisory board member for Novartis, Bristol-Myers Squibb, Ipsen, Roche, Pfizer, Astellas Pharma, Seattle Geneticis, Merck, MSD, AstraZeneca, Exelixis and Peloton Therapeutics. L.A. received research funding from Bristol-Myers Squibb; was a consultant\/advisory board member for Novartis, Amgen, Bristol-Myers Squibb, Ipsen, Roche, Pfizer, Astellas Pharma, Merck, MSD, AstraZeneca, Exelixis, Corvus Pharmaceuticals and Peloton Therapeutics; received travel, accommodations and expenses from Bristol-Myers Squibb and MSD. R.H.G. is the volunteer chair of a nonprofit organisation that receives designated project funding from Pfizer, Bristol-Myers Squibb, Ipsen, Eisai, Exelixis, MSD, Novartis, Roche, Merck and the Merck\/Pfizer Alliance. She has not received any funds personally from any of the above. B.I.R. received a research grant and personal fee from Pfizer, Merck, Bristol-Myers Squibb, AVEO Pharmaceuticals and Roche. He received personal fees from Surface Oncology, Aravive, Synthorx and 3D Medicines.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The advisers who participated in the meeting to discuss the need for differential therapy management guidelines received honoraria from Pfizer for their participation. Support for the literature analysis and medical writing was funded by Pfizer and Merck KGaA. Pfizer and Merck KGaA had no active role in the development of the guidelines reported in this paper. Open access funding provided by Projekt DEAL.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding information"}}]}}